{"id":58296,"date":"2026-02-27T19:22:09","date_gmt":"2026-02-27T11:22:09","guid":{"rendered":"https:\/\/flcube.com\/?p=58296"},"modified":"2026-04-28T12:36:39","modified_gmt":"2026-04-28T04:36:39","slug":"beone-medicines-reports-5-3b-full-year-revenue-brukinsa-drives-40-growth-2026-guidance-raised","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=58296","title":{"rendered":"BeOne Medicines Reports $5.3B Full\u2011Year Revenue \u2013 Brukinsa Drives 40% Growth, 2026 Guidance Raised"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>BeOne Medicines Ltd. (<a href=\"https:\/\/www.google.com\/finance\/quote\/ONC:NASDAQ\">NASDAQ:\u202fONC<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/6160:HKG\">HKG:\u202f6160<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/688235:SHA\">SHA:\u202f688235<\/a>)<\/strong> announced <strong>Q4 and full\u2011year 2025 financial results<\/strong>, with <strong>global revenue reaching USD\u202f5.3\u202fbillion<\/strong> (up <strong>40% YOY<\/strong>) and <strong>GAAP net profit of USD\u202f287\u202fmillion<\/strong>. The company&#8217;s <strong>BTK inhibitor Brukinsa (zanubrutinib)<\/strong> emerged as the primary growth driver, with <strong>global sales of USD\u202f3.9\u202fbillion<\/strong> (+49% YOY), while <strong>2026 revenue guidance<\/strong> is set at <strong>USD\u202f6.2\u20136.4\u202fbillion<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-performance-summary\">Financial Performance Summary<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>Q4\u202f2025<\/th><th>Full\u2011Year\u202f2025<\/th><th>YOY Growth<\/th><\/tr><\/thead><tbody><tr><td><strong>Global Total Revenue<\/strong><\/td><td>USD\u202f1.5\u202fB<\/td><td>USD\u202f5.3\u202fB<\/td><td>Q4: +33%; FY: <strong>+40%<\/strong><\/td><\/tr><tr><td><strong>GAAP Net Profit<\/strong><\/td><td>USD\u202f67\u202fM<\/td><td>USD\u202f287\u202fM<\/td><td>\u2014<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-product-revenue-breakdown\">Product Revenue Breakdown<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Product<\/th><th>Q4\u202f2025<\/th><th>Full\u2011Year\u202f2025<\/th><th>YOY Growth<\/th><\/tr><\/thead><tbody><tr><td><strong>Brukinsa (zanubrutinib)<\/strong> \u2013 Global<\/td><td>USD\u202f1.1\u202fB<\/td><td>USD\u202f3.9\u202fB<\/td><td>Q4: +38%; FY: <strong>+49%<\/strong><\/td><\/tr><tr><td>\u2014 US Sales<\/td><td>USD\u202f845\u202fM<\/td><td>USD\u202f2.8\u202fB<\/td><td>Q4: +37%; FY: <strong>+45%<\/strong><\/td><\/tr><tr><td><strong>Tislelizumab (PD\u20111)<\/strong> \u2013 Global<\/td><td>USD\u202f182\u202fM<\/td><td>USD\u202f737\u202fM<\/td><td>Q4: +18%; FY: <strong>+19%<\/strong><\/td><\/tr><tr><td><strong>Amgen\u2011Licensed Products<\/strong> \u2013 Global<\/td><td>USD\u202f112\u202fM<\/td><td>USD\u202f486\u202fM<\/td><td>Q4: +11%; FY: <strong>+33%<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-2026-revenue-guidance\">2026 Revenue Guidance<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Guidance<\/th><\/tr><\/thead><tbody><tr><td><strong>Full\u2011Year Revenue<\/strong><\/td><td><strong>USD\u202f6.2\u202fB \u2013 6.4\u202fB<\/strong><\/td><\/tr><tr><td><strong>Implied Growth<\/strong><\/td><td>~\u202f17\u201321% vs. 2025<\/td><\/tr><tr><td><strong>Growth Drivers<\/strong><\/td><td>Brukinsa US leadership + European\/global expansion<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-highlights\">Strategic Highlights<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Brukinsa Market Leadership:<\/strong> The <strong>BTK inhibitor<\/strong> continues to capture share from <strong>Imbruvica (ibrutinib)<\/strong> and <strong>Calquence (acalabrutinib)<\/strong> in the US and Europe, driven by <strong>head\u2011to\u2011head efficacy data<\/strong> and <strong>differentiated safety profile<\/strong>.<\/li>\n\n\n\n<li><strong>US Revenue Concentration:<\/strong> With <strong>USD\u202f2.8\u202fbillion<\/strong> (53% of total) from US Brukinsa sales, BeOne demonstrates successful <strong>execution in the world&#8217;s largest oncology market<\/strong>.<\/li>\n\n\n\n<li><strong>Tislelizumab Steady Growth:<\/strong> The <strong>PD\u20111 inhibitor<\/strong> maintains <strong>double\u2011digit growth<\/strong> despite intense domestic competition, supported by <strong>differentiated dosing<\/strong> and <strong>global partnership revenues<\/strong>.<\/li>\n\n\n\n<li><strong>Profitability Inflection:<\/strong> <strong>USD\u202f287\u202fmillion GAAP net profit<\/strong> marks BeOne&#8217;s transition to <strong>sustainable profitability<\/strong> following years of heavy R&amp;D investment.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context\">Market Context<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Factor<\/th><th>Impact<\/th><\/tr><\/thead><tbody><tr><td><strong>BTK Inhibitor Market<\/strong><\/td><td>~\u202f$8\u202fbillion globally; Brukinsa gaining share through superior efficacy in CLL and mantle cell lymphoma<\/td><\/tr><tr><td><strong>China Biotech Globalization<\/strong><\/td><td>BeOne&#8217;s $5.3B revenue and US market success validate Chinese biotech&#8217;s ability to compete with multinational pharma<\/td><\/tr><tr><td><strong>Competitive Dynamics<\/strong><\/td><td>AbbVie&#8217;s Imbruvica faces patent cliffs; BeOne positioned to capture switching patients and treatment\u2011na\u00efve cases<\/td><\/tr><tr><td><strong>Investor Sentiment<\/strong><\/td><td>40% revenue growth + profitability + raised guidance supports valuation premium vs. peers<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding 2026 revenue achievement, Brukinsa market share expansion, and global regulatory milestones. Actual results may differ due to risks including competitive responses, pricing pressure, and reimbursement negotiations.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/BeOne_Q4FY_2025_Earnings_Release_Final.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of BeOne_Q4FY_2025_Earnings_Release_Final.\"><\/object><a id=\"wp-block-file--media-e0c5a9d4-126b-41c5-8ab0-c7ea16d4af55\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/BeOne_Q4FY_2025_Earnings_Release_Final.pdf\">BeOne_Q4FY_2025_Earnings_Release_Final<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/BeOne_Q4FY_2025_Earnings_Release_Final.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-e0c5a9d4-126b-41c5-8ab0-c7ea16d4af55\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>BeOne Medicines Ltd. (NASDAQ:\u202fONC, HKG:\u202f6160, SHA:\u202f688235) announced Q4 and full\u2011year 2025 financial results, with global&#8230;<\/p>\n","protected":false},"author":1,"featured_media":58297,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[2092,27,847,3046,848],"class_list":["post-58296","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-beone-medicines","tag-finanical-reports","tag-hkg-6160","tag-nasdaq-onc","tag-sha-688235"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.7) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>BeOne Medicines Reports $5.3B Full\u2011Year Revenue \u2013 Brukinsa Drives 40% Growth, 2026 Guidance Raised - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"BeOne Medicines Ltd. (NASDAQ:\u202fONC, HKG:\u202f6160, SHA:\u202f688235) announced Q4 and full\u2011year 2025 financial results, with global revenue reaching USD\u202f5.3\u202fbillion (up 40% YOY) and GAAP net profit of USD\u202f287\u202fmillion. The company&#039;s BTK inhibitor Brukinsa (zanubrutinib) emerged as the primary growth driver, with global sales of USD\u202f3.9\u202fbillion (+49% YOY), while 2026 revenue guidance is set at USD\u202f6.2\u20136.4\u202fbillion.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=58296\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BeOne Medicines Reports $5.3B Full\u2011Year Revenue \u2013 Brukinsa Drives 40% Growth, 2026 Guidance Raised\" \/>\n<meta property=\"og:description\" content=\"BeOne Medicines Ltd. (NASDAQ:\u202fONC, HKG:\u202f6160, SHA:\u202f688235) announced Q4 and full\u2011year 2025 financial results, with global revenue reaching USD\u202f5.3\u202fbillion (up 40% YOY) and GAAP net profit of USD\u202f287\u202fmillion. The company&#039;s BTK inhibitor Brukinsa (zanubrutinib) emerged as the primary growth driver, with global sales of USD\u202f3.9\u202fbillion (+49% YOY), while 2026 revenue guidance is set at USD\u202f6.2\u20136.4\u202fbillion.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=58296\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-27T11:22:09+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-28T04:36:39+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/2704.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58296#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58296\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"BeOne Medicines Reports $5.3B Full\u2011Year Revenue \u2013 Brukinsa Drives 40% Growth, 2026 Guidance Raised\",\"datePublished\":\"2026-02-27T11:22:09+00:00\",\"dateModified\":\"2026-04-28T04:36:39+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58296\"},\"wordCount\":380,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58296#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/2704.webp\",\"keywords\":[\"BeOne Medicines\",\"Finanical Reports\",\"HKG: 6160\",\"NASDAQ: ONC\",\"SHA: 688235\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=58296#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58296\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=58296\",\"name\":\"BeOne Medicines Reports $5.3B Full\u2011Year Revenue \u2013 Brukinsa Drives 40% Growth, 2026 Guidance Raised - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58296#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58296#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/2704.webp\",\"datePublished\":\"2026-02-27T11:22:09+00:00\",\"dateModified\":\"2026-04-28T04:36:39+00:00\",\"description\":\"BeOne Medicines Ltd. (NASDAQ:\u202fONC, HKG:\u202f6160, SHA:\u202f688235) announced Q4 and full\u2011year 2025 financial results, with global revenue reaching USD\u202f5.3\u202fbillion (up 40% YOY) and GAAP net profit of USD\u202f287\u202fmillion. The company's BTK inhibitor Brukinsa (zanubrutinib) emerged as the primary growth driver, with global sales of USD\u202f3.9\u202fbillion (+49% YOY), while 2026 revenue guidance is set at USD\u202f6.2\u20136.4\u202fbillion.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58296#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=58296\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58296#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/2704.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/2704.webp\",\"width\":1080,\"height\":608,\"caption\":\"BeOne Medicines Reports $5.3B Full\u2011Year Revenue \u2013 Brukinsa Drives 40% Growth, 2026 Guidance Raised\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58296#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BeOne Medicines Reports $5.3B Full\u2011Year Revenue \u2013 Brukinsa Drives 40% Growth, 2026 Guidance Raised\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"BeOne Medicines Reports $5.3B Full\u2011Year Revenue \u2013 Brukinsa Drives 40% Growth, 2026 Guidance Raised - Insight, China&#039;s Pharmaceutical Industry","description":"BeOne Medicines Ltd. (NASDAQ:\u202fONC, HKG:\u202f6160, SHA:\u202f688235) announced Q4 and full\u2011year 2025 financial results, with global revenue reaching USD\u202f5.3\u202fbillion (up 40% YOY) and GAAP net profit of USD\u202f287\u202fmillion. The company's BTK inhibitor Brukinsa (zanubrutinib) emerged as the primary growth driver, with global sales of USD\u202f3.9\u202fbillion (+49% YOY), while 2026 revenue guidance is set at USD\u202f6.2\u20136.4\u202fbillion.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=58296","og_locale":"en_US","og_type":"article","og_title":"BeOne Medicines Reports $5.3B Full\u2011Year Revenue \u2013 Brukinsa Drives 40% Growth, 2026 Guidance Raised","og_description":"BeOne Medicines Ltd. (NASDAQ:\u202fONC, HKG:\u202f6160, SHA:\u202f688235) announced Q4 and full\u2011year 2025 financial results, with global revenue reaching USD\u202f5.3\u202fbillion (up 40% YOY) and GAAP net profit of USD\u202f287\u202fmillion. The company's BTK inhibitor Brukinsa (zanubrutinib) emerged as the primary growth driver, with global sales of USD\u202f3.9\u202fbillion (+49% YOY), while 2026 revenue guidance is set at USD\u202f6.2\u20136.4\u202fbillion.","og_url":"https:\/\/flcube.com\/?p=58296","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-02-27T11:22:09+00:00","article_modified_time":"2026-04-28T04:36:39+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/2704.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=58296#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=58296"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"BeOne Medicines Reports $5.3B Full\u2011Year Revenue \u2013 Brukinsa Drives 40% Growth, 2026 Guidance Raised","datePublished":"2026-02-27T11:22:09+00:00","dateModified":"2026-04-28T04:36:39+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=58296"},"wordCount":380,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=58296#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/2704.webp","keywords":["BeOne Medicines","Finanical Reports","HKG: 6160","NASDAQ: ONC","SHA: 688235"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=58296#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=58296","url":"https:\/\/flcube.com\/?p=58296","name":"BeOne Medicines Reports $5.3B Full\u2011Year Revenue \u2013 Brukinsa Drives 40% Growth, 2026 Guidance Raised - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=58296#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=58296#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/2704.webp","datePublished":"2026-02-27T11:22:09+00:00","dateModified":"2026-04-28T04:36:39+00:00","description":"BeOne Medicines Ltd. (NASDAQ:\u202fONC, HKG:\u202f6160, SHA:\u202f688235) announced Q4 and full\u2011year 2025 financial results, with global revenue reaching USD\u202f5.3\u202fbillion (up 40% YOY) and GAAP net profit of USD\u202f287\u202fmillion. The company's BTK inhibitor Brukinsa (zanubrutinib) emerged as the primary growth driver, with global sales of USD\u202f3.9\u202fbillion (+49% YOY), while 2026 revenue guidance is set at USD\u202f6.2\u20136.4\u202fbillion.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=58296#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=58296"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=58296#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/2704.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/2704.webp","width":1080,"height":608,"caption":"BeOne Medicines Reports $5.3B Full\u2011Year Revenue \u2013 Brukinsa Drives 40% Growth, 2026 Guidance Raised"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=58296#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"BeOne Medicines Reports $5.3B Full\u2011Year Revenue \u2013 Brukinsa Drives 40% Growth, 2026 Guidance Raised"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/2704.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58296","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=58296"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58296\/revisions"}],"predecessor-version":[{"id":58300,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58296\/revisions\/58300"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/58297"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=58296"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=58296"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=58296"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}